Trial Parameters
Condition Pneumococcal Infections
Sponsor Association Clinique Thérapeutique Infantile du val de Marne
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,369
Sex ALL
Min Age 1 Day
Max Age 18 Years
Start Date 2010-12-13
Completion 2030-01-01
All Conditions
Interventions
observational study
Brief Summary
After 7 then 13 valent pneumococcal conjugate vaccine implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
Eligibility Criteria
Inclusion Criteria: * Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood PCR. Exclusion Criteria: * Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory